Status:

COMPLETED

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Healthy

Eligibility:

MALE

18-50 years

Phase:

PHASE1

Brief Summary

To investigate safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in healthy male volunteers

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • 1\. Healthy male subjects
  • Exclusion criteria:
  • Any relevant deviation from healthy conditions
  • Subjects unable to understand or to comply with study requirements

Exclusion

    Key Trial Info

    Start Date :

    April 1 2013

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2013

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT01835899

    Start Date

    April 1 2013

    End Date

    June 1 2013

    Last Update

    January 22 2016

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    1305.2.1 Boehringer Ingelheim Investigational Site

    Mannheim, Germany

    Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution | DecenTrialz